Clinical trials: Hyperuricemia, Gout
Healthy, Hyperuricemia, Gout
Acute Effects of a Urate-lowering Bacterial Therapeutic on Small Intestinal Transcriptomics and Glycomics in Healthy Subjects
This is a pilot study investigating how a novel probiotic supplement (BEO001), with and without a dietary fiber (beta-glucan), affects the lining of the small intestine in healthy people.
- Trial name
- Bugs4U-MoA (NCT07366749)
- Testing
- BEO001 Probiotic, BEO001 Probiotic + Beta-Glucan
- Where
- Sweden
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Örebro University, Sweden
Gout
Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010
The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout.
- Trial name
- EXCEL (NCT00175019)
- Testing
- Febuxostat, Allopurinol
- Volunteers
- 1,086 people
- Sponsor
- Takeda
Gout, Hyperuricemia
Safety and Efficacy Study of Intravenous Uricase-PEG 20
The purpose of this study is to assess the safety, pharmacokinetics and pharmacodynamics of single intravenous doses of Uricase-PEG 20.
- Trial name
- NCT01021241
- Testing
- Uricase-PEG 20
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- EnzymeRx
Chronic Gout, Hyperuricemia
The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics
Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.
- Trial name
- NCT02956278
- Testing
- Allopurinol
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Gout
Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients
The purpose of this study is to evaluate the efficacy, safety and tolerability of MBX-102 in combination with allopurinol compared to allopurinol alone when administered orally once a day for four weeks to gout patients with an…
- Trial name
- NCT01399008
- Testing
- Arhalofenate, Allopurinol, Colchicine
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Hyperuricemia, Gout
Hmong Microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C)
Investigators seek to quantify the impact of vitamin C on patient outcomes, including serum urate level, gout-related symptoms, and obesity (measured by BMI) in both healthy Hmong adults and in Hmong patients with hyperuricemia…
- Trial name
- NCT04938024
- Testing
- Vitamin C
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Hyperuricemia, Gout
Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
The purpose of the study is to evaluate the safety and effectiveness of MBX-102 compared to placebo when given orally once daily for 4 weeks for the treatment of hyperuricemia in patients with gout.
- Trial name
- NCT01336686
- Testing
- Arhalofenate, Colchicine
- Where
- 12 sites in United States
- Volunteers
- 67 people
- Sponsor
- Gilead Sciences
Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2
The aim of this study is to investigate the relationship between body fat distribution measured by CT scan and related risk factors with the risk of incident metabolic and cardiovascular disease in a prospective cohort study of…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, Diabetes Mellitus, Hypertension
- Trial name
- OCES-2 (NCT06694012)
- Where
- Japan
- Volunteers
- 2,000 people
- Sponsor
- Osaka Metropolitan University
Hyperuricemia, Gout
Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)
The purpose of this Phase I study is to evaluate the safety and tolerability of ALLN-346 in in normal healthy volunteers, in an ascending dose design.
- Trial name
- MAD (NCT04829435)
- Testing
- ALLN-346
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Allena Pharmaceuticals
Gout and Hyperuricemia
SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial
SAVE-Care (Sodium Glucose Cotransporter-2 inhibitors [SGLT2i] As Novel Gout Care) Trial is a double-blind randomized placebo-controlled trial (RCT) designed to assess the effect of empagliflozin on serum urate [SU] levels of gout…
- Trial name
- SAVE-Care (NCT06674109)
- Testing
- Empagliflozin 10 mg
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Gout With Hyperuricemia in Adults
Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
The study is being conducted to evaluate the efficacy, and safety of HR091506 tablets for treatment of gout with hyperuricemia in adults, and to compare the results with febuxostat tablets in the same doses.
- Trial name
- NCT06139393
- Where
- China
- Volunteers
- 765 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetic Nephropathy
Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout
The purpose of this study is to investigate the effect of topiroxostat on urinary albumin excretion and the safety in patients with early stage diabetic nephropathy and hyperuricemia with or without gout.
- Trial name
- UPWARD (NCT02327754)
- Testing
- Topiroxostat BID, (Oral daily dosing for 28 weeks)
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Antiphospholipid Syndrome, Endothelial Dysfunction
The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome
Patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease, but the exact mechanism remained to be elucidated.
- Conditions
- Antiphospholipid Syndrome, Endothelial Dysfunction, Hyperuricemia, Gout
- Trial name
- URIC (NCT01818505)
- Where
- Taiwan
- Volunteers
- 210 people
- Sponsor
- National Taiwan University Hospital
Gout Patients
Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients
The study is designed to evaluate the PK/PD, safety and tolerability of AR882 alone or in combination with febuxostat or allopurinol when administered to gout patients.
- Trial name
- NCT04155918
- Testing
- Group 1: AR882 Alone and in Combination with Febuxostat (FBX), Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)
- Where
- New Zealand
- Volunteers
- 30 people
- Sponsor
- Arthrosi Therapeutics
Hyperuricemia
Zurig (Febuxostat) 40mg Efficacy and Safety Trial
Febuxostat is a potent, nonpurine, selective inhibitor of Xanthine oxidase that exhibits antihyperuricemic activity by reducing the formation of uric acid.
- Trial name
- ZEST (NCT02600780)
- Testing
- Febuxostat, Allopurinol
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Getz Pharma
Refractory Gout
A Study of IN026 in Participants With Refractory Gout
The goal of this clinical study is to learn if IN026 Injection is safe and works to lower uric acid levels in adults with refractory gout (gout that does not respond well to standard treatments).
- Trial name
- NCT07587684
- Testing
- IN026 Injection
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gout
Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
The study will be conducted in two parts. The first is a parallel-group design, evaluating doses of 40 mg, 80 mg or 120 mg BCX-4208.
- Trial name
- NCT00985127
- Testing
- BCX4208
- Where
- 24 sites in United States
- Volunteers
- 99 people
- Sponsor
- BioCryst Pharmaceuticals
Gout, Hyperuricemia
Purine Metabolism Enzyme SNP to Uric Acid Production
Determine whether a relationship exists between polymorphisms of the genes XDH, HPRT1, and PRPS1 and gout, hyperuricemia, or the dose of xanthine oxidase (XO) inhibitors to reach a goal serum uric acid of less than 6 mg/dL.
- Trial name
- NCT01830725
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Keesler Air Force Base Medical Center
Gout, Hyperuricemia
The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults
This is a Phase 1, open-label, fixed-sequence, 3-period, 2-way drug interaction study designed to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of LC350189 and Naproxen when administered alone and in…
- Trial name
- NCT04139824
- Testing
- Xanthine Oxidase Inhibitor, nonsteroidal anti-inflammatory drug
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LG Chem
Asymptomatic Hyperuricemia
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA
This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (verinurad + febuxostat +…
- Trial name
- NCT03316131
- Testing
- Verinurad, Febuxostat, Dapagliflozin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- AstraZeneca